These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


483 related items for PubMed ID: 30257348

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Cyclin-dependent protein kinase inhibitors including palbociclib as anticancer drugs.
    Roskoski R.
    Pharmacol Res; 2016 May; 107():249-275. PubMed ID: 26995305
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cyclin-Dependent Kinase 4 and 6 Inhibitors in Cell Cycle Dysregulation for Breast Cancer Treatment.
    Susanti NMP, Tjahjono DH.
    Molecules; 2021 Jul 24; 26(15):. PubMed ID: 34361615
    [Abstract] [Full Text] [Related]

  • 8. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors.
    Collins I, Garrett MD.
    Curr Opin Pharmacol; 2005 Aug 24; 5(4):366-73. PubMed ID: 15964238
    [Abstract] [Full Text] [Related]

  • 9. The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer.
    Ding L, Cao J, Lin W, Chen H, Xiong X, Ao H, Yu M, Lin J, Cui Q.
    Int J Mol Sci; 2020 Mar 13; 21(6):. PubMed ID: 32183020
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Investigational drugs targeting cyclin-dependent kinases for the treatment of cancer: an update on recent findings (2013-2016).
    Di Giovanni C, Novellino E, Chilin A, Lavecchia A, Marzaro G.
    Expert Opin Investig Drugs; 2016 Oct 13; 25(10):1215-30. PubMed ID: 27606939
    [Abstract] [Full Text] [Related]

  • 13. Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions.
    Klein MA.
    Adv Protein Chem Struct Biol; 2020 Oct 13; 121():115-141. PubMed ID: 32312419
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Naturally Sourced CDK Inhibitors and Current Trends in Structure-Based Synthetic Anticancer Drug Design by Crystallography.
    Nandi S, Dey R, Dey S, Samadder A, Saxena AK.
    Anticancer Agents Med Chem; 2022 Oct 13; 22(3):485-498. PubMed ID: 34503422
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms.
    Senderowicz AM.
    Cancer Chemother Pharmacol; 2003 Jul 13; 52 Suppl 1():S61-73. PubMed ID: 12819936
    [Abstract] [Full Text] [Related]

  • 18. Targeting Cyclin-Dependent Kinases and Cell Cycle Progression in Human Cancers.
    Santo L, Siu KT, Raje N.
    Semin Oncol; 2015 Dec 13; 42(6):788-800. PubMed ID: 26615126
    [Abstract] [Full Text] [Related]

  • 19. 5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases.
    Vymětalová L, Havlíček L, Šturc A, Skrášková Z, Jorda R, Pospíšil T, Strnad M, Kryštof V.
    Eur J Med Chem; 2016 Mar 03; 110():291-301. PubMed ID: 26851505
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 25.